IGF1 and ovarian cancer: BAPTA-AM, a Ca2+ chelator, inhibits calcium channels and reduces intracellular Ca2+ levels, which can significantly reduce IGF-induced migration, invasion, and wound healing of ovarian cancer cells [51].